Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Terns Pharmaceuticals (TERN) Free Cash Flow (2020 - 2023)

Terns Pharmaceuticals (TERN) has disclosed Free Cash Flow for 4 consecutive years, with -$19.4 million as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, Free Cash Flow fell 72.17% year-over-year to -$19.4 million, compared with a TTM value of -$67.4 million through Dec 2023, down 36.57%, and an annual FY2024 reading of -$70.1 million, down 3.88% over the prior year.
  • Free Cash Flow was -$19.4 million for Q4 2023 at Terns Pharmaceuticals, up from -$20.7 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$6.3 million in Q3 2020 and bottomed at -$20.7 million in Q3 2023.
  • Average Free Cash Flow over 4 years is -$11.8 million, with a median of -$11.2 million recorded in 2022.
  • The sharpest move saw Free Cash Flow plummeted 85.82% in 2021, then increased 5.56% in 2022.
  • Year by year, Free Cash Flow stood at -$7.4 million in 2020, then crashed by 46.21% to -$10.9 million in 2021, then fell by 3.46% to -$11.2 million in 2022, then tumbled by 72.17% to -$19.4 million in 2023.
  • Business Quant data shows Free Cash Flow for TERN at -$19.4 million in Q4 2023, -$20.7 million in Q3 2023, and -$13.0 million in Q2 2023.